These drugs treat Alzheimer’s disease by helping improve memory, attention, reason, and language and increasing the levels of brain chemicals to aid memory and judgment. In 2023, lecanemab, sold under ...
The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research ...
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
It’s approved by the Food and Drug Administration (FDA ... the medication and those who were less likely to develop cognitive ...
Alzheimer’s has no cure and can’t be reversed, but the FDA-approved drug can slow cognitive decline. Eli Lilly reported that ...